Overview of Dr. Chari
Dr. Ajai Chari is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Mount Sinai West, Mount Sinai Morningside, Mount Sinai Beth Israel, Mount Sinai Hospital of Queens, Mount Sinai Brooklyn, and UCSF Medical Center. He received his medical degree from David Geffen School of Medicine at UCLA and has been in practice 18 years. Dr. Chari accepts several types of health insurance, listed below. He is one of 122 doctors at Mount Sinai Beth Israel and one of 71 doctors at Mount Sinai Hospital of Queens who specialize in Oncology. He has more than 100 publications and over 500 citings.
Office
1 Gustave L Levy Pl
# 1185
New York, NY 10029Fax+1 212-241-3908
Education & Training
University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2002 - 2005
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1999 - 2002
David Geffen School of Medicine at UCLAClass of 1999
Certifications & Licensure
FL State Medical License 2022 - Present
CA State Medical License 2023 - 2025
NY State Medical License 2000 - 2024
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
Clinical Trials
- Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma Start of enrollment: 2006 Feb 01
- Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis Start of enrollment: 2013 Jan 01
- Phase II, Single-Center, Oral Panobinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma (MM) Start of enrollment: 2012 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- Efficacy and Safety of Daratumumab in Intermediate/High-risk Smoldering Multiple Myeloma: Final Analysis of CENTAURUS.Carl Ola Landgren, Ajai Chari, Yael C Cohen, Andrew Spencer, Peter M Voorhees
Blood. 2024-12-09 - MRD-negative duration following latest line of therapy predicts long-term PFS in real-world multiple myeloma patients.Lucia Y Chen, Santiago Thibaud, Saoirse Bodnar, Ajai Chari, Joshua Richter
Blood Advances. 2024-11-15 - Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes.Santiago Thibaud, Ryan L Subaran, Scott Newman, Alessandro Lagana, David T Melnekoff
Blood Cancer Discovery. 2024-11-01
Journal Articles
- Twice‐Weekly Ixazomib in Combination with Lenalidomide‐Dexamethasone in Patients with Newly Diagnosed Multiple MyelomaMyo Htut, Michaela Liedtke, Stephen D Smith, Craig C Hofmeister, Rachid Baz, Paul G Richardson, Cara A Rosenbaum, David H Vesole, Ajai Chari, Jesus G Berdeja, Noopur Raje, British Journal of Haematology
Abstracts/Posters
- Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with ...Ajai Chari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacy...Ajai Chari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...Ajai Chari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- Subcutaneous Daratumumab Plus Standard Treatment Regimens in Patients with Multiple Myeloma across Lines of Therapy: Pleiades Study Update61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Minimal Residual Disease in Hematologic Malignancies: Testing Considerations and Challenges61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Selinexor-Containing Regimens for the Treatment of Patients with Multiple Myeloma Refractory to Chimeric Antigen Receptor T-Cell (CAR-T) Therapy61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Join now to see all
Authored Content
- Blood Transfusion Management and Transfusion-Related Outcomes in Daratumumab-Treated Patients with Relapsed or Refractory Multiple MyelomaJune 2016
Press Mentions
Studying the Promising Role of Bispecific Antibodies in Multiple Myeloma With Ajai Chari, MDJanuary 31st, 2023- An Antibody Successfully Treats over 70% of Multiple Myeloma Patients in TrialDecember 26th, 2022
- New Cancer Drug Achieves 73% Response Rate in PatientsDecember 12th, 2022
- Join now to see all
Professional Memberships
- Member
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS Tennessee Network 5
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Coventry Carelink Health Plans PPO
Empire BCBS HMO
Empire BCBS PPO
First Health PPO
GHI PPOGreat West PPO
HIP of New York - Select PPO
Humana ChoiceCare Network PPO
MagnaCare PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
